Thursday, April 22, 2021
12:01 PM EST – Zenith Epigenetics Ltd. : Has entered into an agreement with Astellas Pharma Inc. to evaluate ZEN-3694, Zenith’s leading BET inhibitor, in combination with Astellas and Pfizer’s androgen receptor inhibitor, XTANDI (enzalutamide), in patients with metastatic castration resistant prostate cancer (mCRPC). Zenith Epigenetics Ltd. (T.RVX) shares were up $0.02 at 0.93.
Stocks in Play: Zenith Epigenetics Ltd., Thu, 22 Apr 2021 12:12:05 EST